Covid 19 Vaccines: Novavax Receives FDA Authorization for Updated Formula
Covid 19 Vaccines Gain Momentum with Novavax Authorization
The US Food and Drug Administration authorized an updated version of the protein-based Covid 19 vaccines from Novavax for individuals aged 12 and older. The availability of these doses is projected for late next week.
Impact of Updated Covid 19 Vaccines
“The COVID-19 vaccines have had a tremendous positive impact on public health,” stated Dr. Peter Marks, director of the FDA’s Center for Biologics Evaluation and Research. Vaccination remains the most effective method for COVID-19 prevention.
- Updated Covid 19 vaccines provide a new option that meets safety and effectiveness standards.
- Novavax’s protein-based vaccine operates differently from mRNA vaccines.
Current Recommendations and Availability
The CDC recommends everyone over the age of six months to receive both an updated Covid 19 vaccine and a flu shot this year. The Moderna and Pfizer vaccines targeting the KP.2 strain were authorized last week.
- Novavax vaccine to be available in thousands of locations.
- High levels of SARS-CoV-2 virus detected in wastewater.
Expect the Novavax vaccine to support health initiatives as current virus levels remain concerning, with wastewater data indicating high transmission rates.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.